BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cobra Biologics Ltd. Release: Reducing Volume Losses During Fill and Finish


10/22/2013 10:02:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

22 October 2013: The loss of drug product during the filtration and fill process presents a major challenge to pharmaceutical and biologics manufacturers worldwide. For Cobra Biologics, a leading contract manufacturer (CMO) providing aseptic manufacture for all Phases of clinical development, limiting the loss of customers’ valuable product is paramount.

To better accommodate high value, small volume filling, for example with antibody and plasmid APIs, a project was initiated to modify the fill process with the aim of minimising product losses. Careful mapping of the fill process followed by changes in the working procedures and the choice of disposable fluid flow paths, resulted in a more than 10-fold decrease in product waste.

Successful improvement of the process, based on a commercially available system, ensures that a maximum product yield is available for filling and lyophilisation, a factor especially important for small batches of high value drug product.

Cobra will be presenting a poster documenting the findings of this project entitled “Minimising Drug Product Losses in Small Volume Aseptic Filling” at The Universe of Pre-Filled Syringes and Injection Devices PDA conference in Basel, 5-6 November 2013.

Having optimised the filtration process with an impressive reduction in downstream losses to less than 0.1 litre, Cobra’s on-going project will be to further minimise volume losses, enhancing customer product yields, by thorough review of product sampling and validation procedures.

Cobra’s state-of-the-art Fill Finish facility was acquired from UniTech Pharma at the end of 2011 and expands an already comprehensive service offering to include sterile drug product production and freeze drying / lyophilisation for a wide range of batch sizes from 1 to 200 litres. Utilising fully disposable systems affords Cobra increased flexibility for pre-clinical, clinical and commercial manufacture, and customers’ products can be filled in either single-use syringes (0.5 ml – 3ml) or injected vials (0.5ml – 100ml) while meeting rigorous sterility requirements in accordance with aseptic manufacturing procedures.

For more information about Cobra Biologics, please contact Peter Coleman, CEO, on +44 (0)1782 714181 or email peter.coleman@cobrabio.com

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0)207 861 3019 or email: t.jervis@defacto.com

About Cobra Biologics

Cobra Biologics is a leading international contract manufacturing organisation (CMO) of biologics and pharmaceuticals for clinical and commercial supply. Cobra has three GMP approved facilities, each with expertise tailored to serving our customers across the world. We offer a broad range of integrated and stand-alone contract services, stretching from cell line and process development through to fill and finish for the supply of products for clinical trials and the commercial market. We take pride in manufacturing excellence and being a trusted provider, delivering what we promise and helping our customers to develop medicines for the benefit of patients. Cobra supplies manufacturing solutions to the pharmaceutical industry covering antibodies, recombinant proteins, viruses, phage, DNA, whole cell vaccines and therapeutics as well as biologics and small molecule API lyophilisation and fill finish.

For more information please visit: www.cobrabio.com

For media enquiries, please contact Tristan Jervis on: +44 (0) 207 203 6740 or e-mail: t.jervis@defacto.com.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES